Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 16.19
+1.15 (7.65%)
Aug 7, 2026, 4:10 PM AEST
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.48. The average 1-year stock price forecast is 45.03% higher than the current stock price, while the lowest is $18.00 (+11.18%) and the highest is $31.00 (+91.48%).
Price Target: $23.48 (+45.03%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 8 | 8 | 8 | 9 |
| Buy | 4 | 4 | 5 | 6 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $31.00 | Buy | Maintains | $31.00 | +91.48% | Jul 29, 2026 |
| Jarden | Jarden | Buy Maintains $21.10 | Buy | Maintains | $21.10 | +30.33% | Jul 23, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Buy Maintains $24.40 | Buy | Maintains | $24.40 | +50.71% | Jul 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $30.00 | Buy | Maintains | $30.00 | +85.30% | Jul 22, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $22.40 → $23.90 | Buy | Maintains | $22.40 → $23.90 | +47.62% | Jul 22, 2026 |
Financial Forecast
Revenue This Year
943.81M
from 803.79M
Increased by 17.42%
Revenue Next Year
1.09B
from 943.81M
Increased by 15.27%
EPS This Year
0.00
from -0.02
EPS Next Year
0.05
from 0.00
Increased by 1,019.74%
EPS and Forward PE are based on non-GAAP adjusted numbers.